ONCOTYPE DX® ASSAY FOR BREAST CANCER: Personalized, validated, superior to conventional criteria in predicting risk of recurrence—A ROUNDTABLE DISCUSSION AMONG EXPERTSContinue to Article
Chairperson and moderator
Harry D. Bear, MD, PhD
Walter Lawrence, Jr. Distinguished Professor in Oncology
Chairman, Division of Surgical Oncology
Professor of Surgery and Microbiology & Immunology
Virginia Commonwealth University
School of Medicine & VCU Massey Cancer Center
Christine Laronga, MD, FACS
Comprehensive Breast Program
Section Head, Surgical Oncology
H. Lee Moffitt Cancer Center & Research Institute
University of South Florida
David M. Hyams, MD
Director of Surgical Oncology
Comprehensive Cancer Center
Desert Regional Medical Center
Palm Springs, California
Pat Whitworth, MD
Director Nashville Breast Center
Dr Bear reports that he serves on the speakers bureaus for Genomic Health® and Genentech. Dr Hyams reports that he receives grant/research support from AstraZeneca and Ortho Biotech; he also serves as a consultant to Genomic Health and on the speakers bureaus of Genomic Health, Ortho Biotech, and AstraZeneca. Dr Laronga serves on the speakers bureau of Genomic Health. Dr Whitworth serves as a consultant to Genomic Health, Veridex, and Myriad; he also serves on the speakers bureaus of Genomic Health, Veridex, and Myriad.
This article summarizes a roundtable discussion that received financial support from Genomic Health. Both the participants and Genomic Health have modified the original transcript in order to ensure that the information provided is concise and factually correct.
However, the opinions put forth in this article are those of the participants and do not necessarily reflect the views of Genomic Health.